Annual Drug Patent Expirations for OMIDRIA
Omidria is a drug marketed by Rayner Surgical and is included in one NDA. It is available from two suppliers. There are seven patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for OMIDRIA.
This drug has fifty patent family members in thirty-seven countries.
The generic ingredient in OMIDRIA is ketorolac tromethamine; phenylephrine hydrochloride. Two suppliers are listed for this compound. Additional details are available on the ketorolac tromethamine; phenylephrine hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
